ETON · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Eton Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

LATEST CLOSE

42.59 USD

0.6% latest week

Weekly setup

Constructive, but selective

The weekly trend is active. Price is 67.2% above the Trend Line and sits at 92.5% of its 52-week range. The latest completed week returned 0.6%, after a 19.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 67/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high; earnings are due in 7d.

Technical setup score 76/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE	1W RETURN	4W RETURN
42.59 USD	**0.6%**	**19.3%**
24 Jul 2026	latest completed week	short-term follow-through

12W RETURN	TREND BREADTH	VOLUME RATIO
47.4%	**57.7%**	**1.4x**
quarterly tape	30 of 52 weeks active	vs 13-week average

What is working

- The trend backdrop is active with a 17-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.

What could go wrong

- 10 reversal markers appear in the recent smart-money tape.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH	INDICATOR STACK	TREND BACKDROP	PATIENT CAPITAL
0.6%	**77/82**	**Active**	**Quiet**
Latest completed week; four-week move 19.3%.	Trend and activity pressure are weighted against the latest 12-week confirmation window.	The trend backdrop defines the current weekly regime.	Activity-pressure buy-signal status for institutional accumulation timing.

NEXT-WEEK EXPECTANCY

Positive 57.15%

Historical one-week expectancy contributes to the evidence score when direction is confirmed.

OPTIONS PRESSURE

Volatility

67/100 conviction; expected move 19.4%.

NEWS SENTIMENT

54/100

50 relevant articles in the latest sentiment read.

EVENT RISK

7d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is active. Price is 67.2% above the Trend Line and sits at 92.5% of its 52-week range. The latest completed week returned 0.6%, after a 19.3% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range

13.78 USD
44.91 USD

Latest close sits at 92.5% of the 52-week range.

RANGE LOCATION

92.5%

Shows where the latest close sits between the 52-week low and high.

TREND DISTANCE

67.2%

Price premium or discount versus the weekly Trend Line.

FAIR-VALUE GAP

233.7%

Premium demand or model discount versus Sharemaestro Fair Value.

HIGH-WATER GAP

-5.2%

Distance from the latest 52-week high.

02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION	BASELINE	ONE-YEAR BASE	LATEST WEEKLY VOLUME
1.4x	2.1M	1.7M	2.9M
Latest volume versus the 13-week average.	13-week average volume.	52-week average volume.	Most recent completed week.

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.

Activity pressure path



Latest 0.92 · 12-week average 0.87

12-week confirmation

Signal	Read	Meaning
Trend active	12/12	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	12/12	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	12/12	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.92	Current proprietary activity-pressure read.
Buy signals	0	Accumulation signal count in the latest 12 weeks.
Reversal markers	10	10 reversal markers

No recent accumulation markers. 10 reversal markers.

03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is 19.3% over four weeks, 47.4% over 12 weeks, and 176.6% over one year. The current trend has remained active for 17 consecutive weeks.

Performance by holding period

1W	0.6%
4W	19.3%
12W	47.4%
26W	184.1%
52W	176.6%

ACTIVE TREND STREAK
17 weeks
Consecutive active weeks.

ACTIVE WEEKS
30
Latest 52 weeks.

TREND BREADTH
57.7%
Share of active weeks.

Activity pressure vs relative leadership



Blue: activity pressure · Green: relative leadership

PRESSURE
1.61
Latest activity-pressure read.

PRESSURE CHANGE
35.1%
Four-week change in activity pressure.

LEADERSHIP
79.97
Latest relative-leadership reading.

RS CHANGE
41.5%
Four-week change in relative leadership.

Technical setup scorecard

Trend	77
Momentum	100
Activity Pressure	82
Relative Leadership	100
Next-Week Expectancy	79
Volume	58
Smart Money	56
Risk Control	56

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

FACTOR WEEK	STATEMENTS THROUGH	FIELD COVERAGE	MODEL CONFIDENCE
26 Jul 2026	**31 Dec 2025**	**88%**	**84%**
Latest published factor snapshot.	Financial reporting period used.	Available factor fields.	Snapshot confidence.

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength	**39/100**
Value	**3/100**
Quality	**75/100**
Momentum	**97/100**
Growth	**88/100**

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E	**-**
Price divided by trailing earnings.	
PRICE / SALES	**13.4x**
Market value relative to trailing revenue.	
EV / EBITDA	**212.5x**
Enterprise value relative to operating cash earnings.	
FREE-CASH-FLOW YIELD	**1.4%**
Free cash flow as a share of enterprise value.	

Business quality

Margins and the return generated on invested capital.

GROSS MARGIN	**54.8%**
Gross profit retained from each unit of revenue.	
OPERATING MARGIN	**1.5%**
Operating profit retained from revenue.	
FREE-CASH-FLOW MARGIN	**18.7%**
Free cash flow generated from revenue.	
RETURN ON INVESTED CAPITAL	**4.2%**
Operating return generated on invested capital.	

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength

Recent business growth and accounting strength.

REVENUE GROWTH Latest one-year revenue growth.	**79.9%**
EPS GROWTH Latest one-year earnings-per-share growth.	**-**
FREE-CASH-FLOW GROWTH Latest one-year free-cash-flow growth.	**119.2%**
PIOTROSKI F-SCORE Nine-point accounting-strength checklist.	**5/9**

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

DIVIDEND YIELD Cash dividends relative to market value.	**-**
BUYBACK YIELD Net share repurchases relative to market value.	**-0.2%**
SHAREHOLDER YIELD Dividend yield plus net buyback yield.	**-0.2%**
NET DEBT / EBITDA Balance-sheet debt relative to operating cash earnings.	**-1.4x**

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Volatility

ETON shows volatility options pressure with a 67/100 conviction score, put-call volume ratio of 0.04, expected move of 19.4%, and Sharemaestro trend signal active.

CONVICTION

67/100

Options signal conviction.

EXPECTED MOVE

19.4%

Nearest-chain pricing.

PUT/CALL VOLUME

0.04

Contract volume balance.

Pressure	96
Speculation	41
Volatility	94
Trend agreement	30

Insider activity

6 / 14

6 acquisitions and 14 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

54/100

Weighted news tone is neutral across 50 relevant articles.

17 positive · 27 neutral · 6 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal

06 · CATALYSTS AND RISK

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS	OPTIONS EXPECTED MOVE	52-WEEK DRAWDOWN	13-WEEK VOLATILITY
7d	19.4%	-5.2%	8.3%
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.	Nearest-chain priced movement where available.	Distance below the 52-week high.	Standard deviation of weekly returns.

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER	BEST WEEK	WORST WEEK	LATEST WEEK
18 of 26	+25.5%	-8.1%	+0.6%
8 weeks finished lower.	Week of 1 May.	Week of 24 Apr.	Week of 24 Jul.

Shape of recent returns

Strong gains	13
Modest gains	5
Flat weeks	-
Modest losses	3
Sharp losses	5

RECENT VOL	BASE VOL
8.3%	7.6%
13-week weekly-return volatility.	52-week weekly-return volatility.

UP/DOWN SPLIT	AVERAGE SKEW
29/23	7.0% / -3.7%
Count of positive and negative weeks in the 52-week window.	Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
- / 100	**1.3%**	**51.0%**
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Drug Manufacturers - Specialty & Generic

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
4 / 74	**-1.2%**	**37.8%**
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ZYBT	NASDAQ	147.9%	142.5%	Inactive
TLPH	NASDAQ	1.9%	31.1%	Active
CABR	NASDAQ	11.5%	19.8%	Active
ETON	NASDAQ	0.6%	19.3%	Active
OPTH	NASDAQ	-6.6%	14.4%	Inactive

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	74/100	Trend, activity pressure, participation, and risk combine to a 74/100 tape read.	
Indicator analysis	82/100	Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.	Activity pressure 0.92; 10 reversal markers
Next-Week Expectancy	Positive 57.15%	Next-week expectancy is positive with a 57.15% historical one-week setup read.	Adds short-term historical context without overriding trend, activity, or relative leadership.
Factors	52/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 73; Small Cap Core rank 99
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	48/100	ETON shows volatility options pressure with a 67/100 conviction score, put-call volume ratio of 0.04, expected move of 19.4%, and Sharemaestro trend signal active.	Volatility · Volatility expansion watch · Expected move 19.4%
Sentiment	54/100	Weighted news tone is neutral across 50 relevant articles.	Eton Pharmaceuticals Files FDA Supplement Seeking to Expand KHINDIVI Pediatric Indication
Insiders	6 / 14	6 acquisitions and 14 disposals in the latest 180-day insider tape.	
Earnings	7d	Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH
0.6%
Latest completed week; four-week move 19.3%.

INDICATOR STACK
77/82
Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP
Active
The trend backdrop defines the current weekly regime.

PATIENT CAPITAL
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.

NEXT-WEEK EXPECTANCY
Positive 57.15%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.

OPTIONS PRESSURE
Volatility
67/100 conviction; expected move 19.4%.

NEWS SENTIMENT
54/100
50 relevant articles in the latest sentiment read.

EVENT RISK
7d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	42.59 USD	0.6%	25.47 USD	12.76 USD	1.61	79.97	2.9M	On
17 Jul 2026	42.32 USD	15.6%	24.61 USD	12.51 USD	1.57	79.46	3.1M	On
10 Jul 2026	36.61 USD	-2.4%	23.75 USD	12.26 USD	1.42	51.72	1.8M	On
03 Jul 2026	37.50 USD	5.0%	23.08 USD	12.04 USD	1.34	60.47	2.1M	On
26 Jun 2026	35.70 USD	9.9%	22.37 USD	11.82 USD	1.19	56.51	2.7M	On
19 Jun 2026	32.48 USD	2.8%	21.72 USD	11.61 USD	1.02	38.04	1.4M	On
12 Jun 2026	31.59 USD	8.4%	21.19 USD	11.43 USD	1.18	39.36	1.5M	On
05 Jun 2026	29.13 USD	-4.3%	20.70 USD	11.25 USD	1.30	32.82	2.1M	On
29 May 2026	30.45 USD	-6.6%	20.29 USD	11.09 USD	1.50	33.36	1.6M	On
22 May 2026	32.59 USD	7.7%	19.88 USD	10.92 USD	1.62	47.30	2.5M	On
15 May 2026	30.26 USD	2.1%	19.41 USD	10.74 USD	1.36	38.98	1.7M	On
08 May 2026	29.65 USD	2.6%	19.00 USD	10.57 USD	1.35	36.27	2.6M	On
01 May 2026	28.90 USD	25.5%	18.67 USD	10.40 USD	1.30	40.77	1.8M	On
24 Apr 2026	23.02 USD	-8.1%	18.37 USD	10.24 USD	1.37	14.39	1.4M	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Open the live report · Open the interactive chart · Full disclaimer